title: Active immunization alters the plasma nicotine concentration in rats.
abstract: The ability of active immunization to alter nicotine distribution was studied in rats. Animals were immunized with 6-(carboxymethylureido)-(+/-)-nicotine (CMUNic) linked to keyhole limpet hemocyanin (KLH). Antibody titers determined by ELISA, using CMUNic coupled to albumin as the coating antigen, were greater than 1:10,000. Antibody binding was inhibited by neither of the nicotine metabolites cotinine and nicotine-N-oxide but was inhibited to a greater extent by CMUNic than by nicotine; this suggests the presence of antibodies to the linker structure as well as antibodies to nicotine. Antibody affinity for nicotine measured by soluble radioimmunoassay was 2.4 +/- 1.6 x 10(7) M-1, and binding capacity was 1.3 +/- 0.7 x 10(-6) M, which corresponds to 0.1 +/- 0.05 mg/ml of nicotine-specific IgG per milliliter of serum. One week after their second boost, groups of eight anesthetized rats immunized with either CMUNic-KLH or KLH alone received nicotine 0.03 mg/kg (equivalent to two cigarettes in a human) via the jugular vein over 10 sec. This dosing regimen was shown to mimic the arterio-venous nicotine concentration gradient typical of nicotine delivered by cigarette smoking in humans. Plasma nicotine concentrations at 10 to 40 min were 4 to 6-fold higher in the CMUNic-KLH rats than in controls (P < .001). Nicotine binding in plasma determined by equilibrium dialysis was markedly increased in the CMUNic-KLH group (83.4 +/- 6.8% vs. 16.4 +/- 14.2%), but brain nicotine concentrations at 40 min did not differ (37.9 +/- 4.5 vs. 44.0 +/- 8. 4 ng/g, CMUNic-KLH vs. KLH, P = .1). The amount of nicotine bound to antibody in plasma, estimated from the in vivo data, was 9% of the administered dose. These data demonstrate that active immunization can bind a significant fraction of a clinically relevant nicotine dose in plasma. Observing this effect with antibodies of modest affinity and titer is encouraging, but better immunogens may be needed to alter nicotine distribution to brain and modify nicotine's behavioral effects.
authors.affiliation: Minneapolis Medical Research Foundation, Minneapolis, Minnesota, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Hieda
authors.forename: D E
authors.initials: DE
authors.lastname: Keyler
authors.forename: J T
authors.initials: JT
authors.lastname: Vandevoort
authors.forename: J K
authors.initials: JK
authors.lastname: Kane
authors.forename: C A
authors.initials: CA
authors.lastname: Ross
authors.forename: D E
authors.initials: DE
authors.lastname: Raphael
authors.forename: R S
authors.initials: RS
authors.lastname: Niedbalas
authors.forename: P R
authors.initials: PR
authors.lastname: Pentel
mesh_terms: D000818:Animals; D001798:Blood Proteins / Q000378:metabolism; D008297:Male; D009538:Nicotine / Q000276:immunology* / Q000493:pharmacokinetics*; D011485:Protein Binding; D051381:Rats; D014611:Vaccination
chemical_list: D001798:Blood Proteins; D009538:Nicotine